查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1790258

美國照護現場藥物濫用檢測市場規模、佔有率及趨勢分析報告：按產品、樣本類型、技術、最終用途和細分市場進行預測，2025 年至 2033 年

U.S. Point of Care Drug of Abuse Testing Market Size, Share & Trends Analysis Report By Product, By Sample Type, By Technology, By End-use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

美國照護現場藥物濫用檢測市場概況

據估計，2024 年美國照護現場藥物濫用檢測市場規模將達到 3.7055 億美元，預計 2025 年至 2033 年的複合年成長率將達到 9.3%。這一市場的成長動力源於在多種環境下進行快速現場藥物檢測的需求日益成長。照護現場診斷 DOA 檢測（包括尿液、唾液，有時還有血液檢測）廣泛應用於職場、急診室、警察局、復健中心、學校等。這些檢測可立即提供結果，幫助醫療專業人員和機構更快地做出與患者照護、依從性和風險緩解相關的決策。它們的便攜性和易用性進一步推動了實驗室以外專業人士對其的採用，從而促進了市場滲透。

市場促進因素之一是美國藥物濫用氾濫，尤其是鴉片類藥物、大麻、古柯鹼和安非他命。根據美國國家藥物濫用統計中心的數據，到2023年，將有超過2,000萬12歲及以上的美國人患有藥物濫用障礙。這一日益成長的趨勢推動了對高效藥物篩檢工具的需求，尤其是在緊急和職業健康環境中。此外，來自聯邦機構（例如藥物濫用和精神健康服務管理局 (SAMHSA)）和州級鴉片類藥物應對計畫的資金增加，也推動了快速檢測工具的普及。

交通運輸、建築和醫療保健等安全關鍵行業強制要求進行入職前、隨機和事故後藥物檢測，這極大地促進了市場成長。美國運輸部(DOT) 和其他監管機構已實施嚴格要求，強制雇主實施 DOA篩檢通訊協定。在這些環境中，POC 檢測尤其重要，因為它能夠快速識別中毒和近期吸毒情況，有助於減輕法律責任並確保工人安全。

目錄

第1章調查方法與範圍

第2章執行摘要

第 3 章美國照護現場藥物濫用檢測市場變數、趨勢與範圍

  • 市場介紹/電網展望
  • 市場規模和成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • 美國照護現場藥物濫用檢測市場分析工具
    • 波特分析
    • PESTEL分析

第4章。美國照護現場藥物濫用檢測市場（按產品、估計和趨勢分析）

  • 美國照護現場藥物濫用檢測市場：產品差異分析
  • 按產品分類，2024 年和 2033 年
  • 免疫檢測條和測試盒
  • 口腔液體檢測套組
  • 呼吸分析儀
  • 尿液收集杯
  • 數位/可攜式分析儀

第5章美國照護現場藥物濫用檢測市場（按樣本類型、估計和趨勢分析）

  • 美國照護現場藥物濫用檢測市場：樣本類型變異分析
  • 樣本顯示，2024 年和 2033 年
  • 尿
  • 唾液（口腔液體）
  • 呼吸
  • 血
  • 汗水/頭髮

第6章。美國照護現場藥物濫用檢測市場（按技術、估計和趨勢分析）

  • 美國照護現場藥物濫用檢測市場：技術變革分析
  • 按技術分類，2024 年和 2033 年
  • 橫向流動化驗（LFA）
  • 層析法免疫檢測
  • 酵素免疫分析法（ELISA）
  • 質譜法（可攜式或混合式 POC 裝置）

第7章。美國照護現場藥物濫用檢測市場最終用途、預測與趨勢分析

  • 美國照護現場藥物濫用檢測市場：最終用途變異分析
  • 依最終用途，2024 年和 2033 年
  • 醫院和急診部
  • 職場和職業健康中心
  • 居家醫療和遠端用戶
  • 其他

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司分類
  • 公司熱圖分析
  • 公司簡介
  • 公司簡介/上市公司
    • Abbott
    • Quest Diagnostics Inc
    • Thermo Fisher Scientific
    • OraSure Technologies
    • Siemens Healthineers
    • F. Hoffmann-La Roche Ltd.
    • Dragerwerk AG & Co. KGaA
    • Premier BIoTech
    • American Screening Corporation, Inc.
    • Aegis Sciences Corporation
    • MP Biomedicals
    • Innovacon（Alere, Abbott）
Product Code: GVR-4-68040-659-9

U.S. Point Of Care DOA Testing Market Summary

The U.S. point of care drug of abuse (DOA) testing market size was estimated at USD 370.55 million in 2024 and is projected to grow at a CAGR of 9.3% from 2025 to 2033. The market is driven by an increasing need for rapid and on-site drug testing across multiple settings. Point-of-care DOA tests, which include urine, saliva, and occasionally blood-based panels, are widely used in workplaces, emergency departments, law enforcement, rehabilitation centers, and schools. These tests offer immediate results, helping healthcare professionals and institutions make faster decisions related to patient care, compliance, and risk mitigation. Their portability and ease of use are further increasing their adoption among non-laboratory professionals, contributing to market penetration.

One of the primary market drivers is the escalating incidence of drug abuse in the U.S., particularly related to opioids, cannabis, cocaine, and amphetamines. According to the National Center for Drug Abuse Statistics, over 20 million Americans aged 12 and older had a substance use disorder in 2023. This rising trend has heightened the demand for efficient drug screening tools, particularly in emergency and occupational health settings. Additionally, increased funding from federal agencies such as SAMHSA (Substance Abuse and Mental Health Services Administration) and state-level opioid response programs has bolstered the adoption of rapid testing tools.

Mandates for pre-employment, random, and post-incident drug testing in safety-sensitive industries such as transportation, construction, and healthcare are significantly contributing to market growth. The U.S. Department of Transportation (DOT) and other regulatory bodies have stringent requirements that compel employers to implement DOA screening protocols. POC testing is especially valued in these settings for its ability to quickly identify intoxication or recent drug use, helping mitigate legal liability and ensure workforce safety.

U.S. Point of Care Drug of Abuse Testing Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. point of care drug of abuse (DOA) testing market report based on product, sample type, technology, and end-use:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Immunoassay Test Strips and Cassettes
  • Oral Fluid Testing Kits
  • Breath Analyzers
  • Urine Collection Cups
  • Digital/Portable Analyzers
  • Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Urine
  • Saliva (Oral Fluid)
  • Breath
  • Blood
  • Sweat/Hair
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Lateral Flow Assay (LFA)
  • Chromatographic Immunoassays
  • Enzyme-linked Immunosorbent Assay (ELISA)
  • Mass Spectrometry (Portable or Hybrid POC Units)
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Emergency Departments
  • Workplace & Occupational Health Center
  • Home Care & Remote Users
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Point of Care Drug of Abuse (DOA) Testing Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Rising substance abuse rates and opioid crisis
      • 3.3.1.2. Increased adoption in workplace and law enforcement
      • 3.3.1.3. Shift toward non-invasive and rapid testing methods
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Stringent Regulations
    • 3.3.3. Market Opportunities Analysis
    • 3.3.4. Market Challenges Analysis
      • 3.3.4.1. Product Recalls
  • 3.4. U.S. Point of Care Drug of Abuse (DOA) Testing Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Product Estimates & Trend Analysis

  • 4.1. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Product Movement Analysis
  • 4.2. U.S. Point of Care Drug of Abuse (DOA) Testing Market Estimates and Forecasts, by Product (USD Million), 2024 & 2033
  • 4.3. Immunoassay Test Strips and Cassettes
    • 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Oral Fluid Testing Kits
    • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Breath Analyzers
    • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Urine Collection Cups
    • 4.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Digital/Portable Analyzers
    • 4.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Sample Type Estimates & Trend Analysis

  • 5.1. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Sample Movement Analysis
  • 5.2. U.S. Point of Care Drug of Abuse (DOA) Testing Market Estimates and Forecasts, by Sample (USD Million), 2024 & 2033
  • 5.3. Urine
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Saliva (Oral Fluid)
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Breath
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Blood
    • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Sweat/Hair
    • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Technology Estimates & Trend Analysis

  • 6.1. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Technology Movement Analysis
  • 6.2. U.S. Point of Care Drug of Abuse (DOA) Testing Market Estimates and Forecasts, by Technology (USD Million), 2024 & 2033
  • 6.3. Lateral Flow Assay (LFA)
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Chromatographic Immunoassays
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Mass Spectrometry (portable or hybrid POC units)
    • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Point of Care Drug of Abuse (DOA) Testing Market: End Use Estimates & Trend Analysis

  • 7.1. U.S. Point of Care Drug of Abuse (DOA) Testing Market: End-use Movement Analysis
  • 7.2. U.S. Point of Care Drug of Abuse (DOA) Testing Market Estimates and Forecasts, by End-use (USD Million), 2024 & 2033
  • 7.3. Hospitals & Emergency Departments
    • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Workplace & Occupational Health Center
    • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Home Care & Remote Users
    • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Others
    • 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
  • 8.5. Company Profiles/Listing
    • 8.5.1. Abbott
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Quest Diagnostics Inc
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Thermo Fisher Scientific
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. OraSure Technologies
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Siemens Healthineers
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. F. Hoffmann-La Roche Ltd.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Dragerwerk AG & Co. KGaA
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Premier Biotech
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. American Screening Corporation, Inc.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Aegis Sciences Corporation
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. MP Biomedicals
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. Innovacon (Alere, Abbott)
      • 8.5.12.1. Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Product Benchmarking
      • 8.5.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 3 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By Sample Type, 2021 - 2033 (USD Million)
  • Table 4 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 5 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 U.S. point of care drug of abuse (DOA) testing market- Key market driver analysis
  • Fig. 7 U.S. point of care drug of abuse (DOA) testing market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 U.S. point of care drug of abuse (DOA) testing market - Porter's analysis
  • Fig. 10 U.S. point of care drug of abuse (DOA) testing market - PESTEL analysis
  • Fig. 11 U.S. point of care drug of abuse (DOA) testing market product outlook key takeaways
  • Fig. 12 U.S. point of care drug of abuse (DOA) testing market: Product movement analysis
  • Fig. 13 Immunoassay Test Strips and Cassettes
  • Fig. 14 Oral Fluid Testing Kits market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Breath Analyzers market estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Urine Collection Cups market estimates, 2021 - 2033 (USD Million)
  • Fig. 17 Digital/Portable Analyzers market estimates, 2021 - 2033 (USD Million)
  • Fig. 18 U.S. point of care drug of abuse (DOA) testing market sample type outlook key takeaways
  • Fig. 19 U.S. point of care drug of abuse (DOA) testing market: sample type movement analysis
  • Fig. 20 Urine market estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Saliva (Oral Fluid) market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Breath market estimates, 2021 - 2033 (USD Million)
  • Fig. 23 Blood market estimates, 2021 - 2033 (USD Million)
  • Fig. 24 Sweat/Hair market estimates, 2021 - 2033 (USD Million)
  • Fig. 25 U.S. point of care drug of abuse (DOA) testing market technology outlook key takeaways
  • Fig. 26 U.S. point of care drug of abuse (DOA) testing market: technology movement analysis
  • Fig. 27 Lateral Flow Assay (LFA) market estimates, 2021 - 2033 (USD Million)
  • Fig. 28 Chromatographic Immunoassays market estimates, 2021 - 2033 (USD Million)
  • Fig. 29 Enzyme-Linked Immunosorbent Assay (ELISA) market estimates, 2021 - 2033 (USD Million)
  • Fig. 30 Mass Spectrometry (portable or hybrid POC units) market estimates, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. point of care drug of abuse (DOA) testing market end use outlook key takeaways
  • Fig. 32 U.S. point of care drug of abuse (DOA) testing market: sample type movement analysis
  • Fig. 33 Urine market estimates, 2021 - 2033 (USD Million)